Quanterix stock surges on CMS' reimbursement rate for LucentAD Alzheimer blood biomarker test.

Quanterix Corp. shares rose 4% on Wednesday after the CMS released a preliminary Clinical Lab Fee Schedule, listing the company's LucentAD Alzheimer blood biomarker test at a maximum reimbursement of $897. The test is used alongside clinical judgment to aid in the diagnosis of Alzheimer's disease.

Quanterix Corp. (QTRX) shares rose by approximately 4% on Wednesday morning following the Centers for Medicare & Medicaid Services (CMS) release of the preliminary Clinical Lab Fee Schedule. The schedule lists the company's LucentAD Alzheimer blood biomarker test at a maximum reimbursement of $897 Quanterix rises on CMS price for LucentAD Alzheimer blood biomarker test^[1]. This news has been well-received by investors, as it signifies a potential increase in reimbursement for the test, which is used alongside clinical judgment to aid in the diagnosis of Alzheimer's disease.

The LucentAD test is designed to detect amyloid pathology, a key indicator of Alzheimer's, and is also used to determine the suitability of patients for drugs that treat the disease. The CMS fee schedule is updated annually, with the preliminary schedule released in September and the final schedule in November. Analysts have noted that the pricing of blood biomarker tests by CMS remains limited, making this development a "meaningful positive" for Quanterix Quanterix rises on CMS price for LucentAD Alzheimer blood biomarker test^[1].

The Alzheimer's blood diagnostics market is competitive, with other players such as CN2 Diagnostics' Precivity and Fujirebio's Lumipulse assays also in the mix. The Precivity assay is priced at $750, while the Lumipulse cerebrospinal fluid assay is $260. The pricing for the Lumipulse blood-based biomarker test remains undetermined Quanterix rises on CMS price for LucentAD Alzheimer blood biomarker test^[1].

Leerink Partners rates Quanterix at market perform, indicating that the company's stock is expected to perform in line with the broader market. The recent earnings call for Quanterix reported a GAAP EPS of -$0.77, which missed expectations by $0.36, and revenue of $24.5M, which fell short by $5.23M Quanterix rises on CMS price for LucentAD Alzheimer blood biomarker test^[1]. Despite these earnings misses, the company's focus on developing innovative diagnostic tools continues to attract investor attention.

In summary, the CMS pricing for Quanterix's LucentAD Alzheimer blood biomarker test at $897 has driven investor optimism, with shares rising by 4% on Wednesday. The company's stock is currently rated at market perform, reflecting a cautious but optimistic outlook from analysts. The competitive landscape in Alzheimer's blood diagnostics highlights the need for Quanterix to continue innovating and securing favorable reimbursement rates to maintain its market position.